甲型流感病毒RNA聚合酶——抗病毒药物靶点  

RNA Polymerase of Influenza A Virus:an Anti-influenza Viral Drug Target

作　　者：罗芬[1] 马卫列[1] 张志珍[1] 

机构地区：[1]广东医学院生物化学与分子生物学教研室,广东东莞523808

出　　处：《中国生物化学与分子生物学报》2014年第5期434-440,共7页Chinese Journal of Biochemistry and Molecular Biology

基　　金：东莞市高等院校科研机构科技计划项目(No.2011108101007)资助~~

摘　　要：甲型流感病毒的RNA聚合酶由PB1、PB2和PA三个亚基组成,在病毒的生命周期中负责行使病毒基因组的转录与复制等多方面功能.甲型流感病毒由于频繁变异,导致其对传统抗病毒药物的敏感性降低,因此开发疗效好、针对性强、毒性低的新型抗病毒药物已成为当前亟待解决的问题.由于RNA聚合酶是甲型流感病毒生命周期重要的调控蛋白,并且编码聚合酶各亚基的基因序列具有高度保守性,故成为当前抗病毒药物的重要靶点.The RNA polymerase of influenza A virus is comprised of trimeric subunits PBI, PB2 and PA, conducting the transcription and replication of the segmented viral RNA genome in the nuclei of infected cells. The development of influenza A virus resistance to traditional antiviral drugs is because the virus is antigenically labile. Therefore, to develop effective new generation anti-influenza drugs with low toxicity and targeting capability frequently meets the problem. The influenza viral RNA polymerase is the most important regulatory protein for the virus life cycle, exerting a high degree of conservation at the genomic level, thus theoretically can be a potential anti-influenza drug targets.

关 键 词：甲型流感病毒 RNA聚合酶 药物靶点 

分 类 号：Q71[生物学—分子生物学] R373.13[医药卫生—病原生物学]